Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaolu Ma has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analysis of prognostic factors and construction of a nomogram for patients with brain metastases from cancer of unknown primary based on the SEER database

    by Xiaolu Ma, Chuanxia Zhang, Xiaoxi Wan, Heng Lu, Mengyuan Kang, Qianhao Meng, Guangru Xu

    Cancer of unknown primary with brain metastases (CUP-BM) represents a distinct and challenging disease entity characterized by an extremely poor prognosis. Currently, there is a lack of systematic research on its prognostic factors. This study aimed to analyze the prognostic factors associated with CUP-BM. Patients diagnosed with CUP-BM between 2010 and 2022 were identified from the SEER database. Kaplan-Meier survival curves were utilized to analyze survival differences among various histological subtypes. Univariate and multivariate Cox proportional hazards regression analyses were employed to identify prognostic factors and construct a prognostic nomogram model. Subgroup analysis was conducted to assess the robustness of age as a prognostic factor and explore potential interaction effects with other variables. A total of 700 eligible CUP-BM patients were included. The neuroendocrine subtype demonstrated the most favorable prognosis. Multivariate analysis revealed that histological type, chemotherapy, liver metastasis, lung metastasis, bone metastasis, and age were independent prognostic factors for overall survival (OS). The constructed nomogram exhibited satisfactory predictive performance (bias-corrected C-index = 0.663). Subgroup analysis showed that age remained a significant prognostic factor in most clinical strata, although its effect varied across subgroups defined by metastatic burden and histological subtype. Neuroendocrine histology and chemotherapy were associated with improved survival, while adenocarcinoma histology, age greater than 60 years, and the presence of liver, lung, or bone metastasis were identified as poor prognostic factors for CUP-BM. The nomogram exhibited good calibration and discrimination capability for prognostic prediction in CUP-BM patients. Notably, the prognostic impact of age was substantially attenuated in patients with extensive metastatic burden, highlighting the importance of individualized risk assessment.

  • Open Access

    Early Antibiotic Exposure and Bronchopulmonary Dysplasia in Very Preterm Infants at Low Risk of Early-Onset Sepsis

    by Wei Shi, Zheng Chen, Liping Shi, Siyuan Jiang, Jianguo Zhou, Xinyue Gu, Xiaoping Lei, Tiantian Xiao, Yanping Zhu, Aimin Qian, et al.

    Early-onset sepsis (EOS) poses a substantial risk to very preterm infants, necessitating the prevalent administration of empirical antibiotics in the neonatal intensive care unit (NICU). Puopolo et al1 reported that more than one-third of the extremely preterm infants in their study were categorized as low risk for EOS, with an incidence of 0.5%. In these low-risk groups, prolonged empirical antibiotic treatment (≥5 days) was observed in approximately 35% of cases.1 Recent studies1-3 have suggested a potential association of prolonged antibiotic therapy with both increased mortality and a higher incidence of adverse neonatal outcomes, including bronchopulmonary dysplasia (BPD), within this vulnerable population. However, these studies often relegated BPD as a secondary outcome, lacking comprehensive consideration of relevant confounding factors. Moreover, the literature has reported inconsistent results in this domain.4-6 The reported association may be influenced by factors such as culture-proven sepsis bacteremia, illness severity, and early respiratory disease.


  • Open Access

    New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges

    by Wenyuan Ma, Hui Wu, Yiran Chen, Hongxia Xu, Junjie Jiang, Bang Du, Mingyu Wan, Xiaolu Ma, Xiaoyu Chen, Lili Lin, et al.

    Despite a standardized diagnostic examination, cancer of unknown primary (CUP) is a rare metastatic malignancy with an unidentified tissue of origin (TOO). Patients diagnosed with CUP are typically treated with empiric chemotherapy, although their prognosis is worse than those with metastatic cancer of a known origin. TOO identification of CUP has been employed in precision medicine, and subsequent site-specific therapy is clinically helpful. For example, molecular profiling, including genomic profiling, gene expression profiling, epigenetics and proteins, has facilitated TOO identification. Moreover, machine learning has improved identification accuracy, and non-invasive methods, such as liquid biopsy and image omics, are gaining momentum. However, the heterogeneity in prediction accuracy, sample requirements and technical fundamentals among the various techniques is noteworthy. Accordingly, we systematically reviewed the development and limitations of novel TOO identification methods, compared their pros and cons and assessed their potential clinical usefulness. Our study may help patients shift from empirical to customized care and improve their prognoses.


  • An Object In Between

    by Xiaolu Ma

    By interrogating how the original composition and textual reincarnations of Lu Xun's “Diary of a Madman” manifest his idea of an “object in between,” this article celebrates an intertextual event in world literature. It traces how Lu Xun's “Diary of a Madman” came into being in conversation with preexisting literary creations and how the intertextual recasting of Lu Xun's story both within and beyond the Sinophone world incorporates postcolonial contexts and recent cyberculture. The intertextuality not only calls for a dynamic negotiation with Lu Xun's “Diary of a Madman” but also involves unexpected engagement with the literary antecedents to Lu Xun's work. By examining the transculturation of cannibalism and insanity in the works of Lu Xun, Liang Wern Fook, Ōe Kenzaburō, and Leonid Andreev, among others, this article reveals how “Diary of a Madman” as an object in between projects a vision of a future that resists the pressures of historical impasse.

  • Open Access

    Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis

    by Xiaolu Ma, Yongfeng Ding, Jiong Qian, Mingyu Wan, Xiaoyu Chen, Nong Xu

    Background. Chemoimmunotherapy has become the first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). We aimed to compare the efficacy and toxicity of different chemoimmunotherapy combinations to determine the optimal treatment option. Methods. PubMed, Web of Science, Cochrane Library, Embase, and abstracts of recent relevant meetings were searched to identify phase III randomized controlled trials (RCTs) of first-line programmed cell death-1 (PD-1)/its receptor (PD-L1) inhibitors plus chemotherapy for ESCC up to July 2022. A network meta-analysis (NMA) following Bayesian approaches was conducted in R software. Result. Our study included six RCTs and 3,611 patients. According to the NMA, toripalimab plus chemotherapy ranked first to prolong overall survival (OS). Sintilimab plus chemotherapy and camrelizumab plus chemotherapy consistently yielded the greatest benefits regarding progression-free survival (PFS). The maximal complete response rate (CRR) and objective response rate (ORR) were achieved with nivolumab plus chemotherapy. Tislelizumab plus chemotherapy attained the highest likelihood of achieving a disease control rate (DCR). The addition of immunotherapy to chemotherapy was associated with improved survival and increased adverse events. Subgroup analysis revealed that patients with PD-L1 tumor positive score (TPS) 10 showed a better OS than those with lower values when undergoing first-line chemoimmunotherapy. Anti-PD-1 inhibitor with platinumpluspaclitaxel (TP) regimen showed a superior PFS benefit over anti-PD-1 inhibitor with platinumplusfluorouracil (FP) regimen. Conclusion. The NMA analysis suggested that sintilimab plus chemotherapy was the preferred regimen for treatment-naive advanced ESCC patients with the best balance between efficacy and safety. Anti-PD-1 inhibitors with the TP regimen were associated with more favorable PFS than those with the FP regimen.


  • Open Access

    Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy

    by Xiaolu Ma, Yongfeng Ding, Jiong Qian, Mingyu Wan, Ning Li, Chenyu Mao, Cheng Xiao, Haiping Jiang, Yulong Zheng, Luntao Wu, et al.

    Background. Chemoimmunotherapy has become the first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC). Still, reliable biomarkers to identify patients who could benefit from this combined therapy remain uncertain. This study focused on elucidating the predictive significance of the monocyte-to-lymphocyte ratio (MLR) and establishing the prognostic nomogram for unresectable ESCC treated with chemoimmunotherapy. Methods. Data of clinical features, peripheral blood parameters, and treatment records were collected in unresectable ESCC patients who received PD-1/PD-L1 inhibitors plus chemotherapy as the first-line treatment from September 2017 to August 2021. The nomogram based on MLR and clinical parameters for predicting the overall survival (OS) was developed and validated. Results. Out of 81 patients enrolled, patients with a lower MLR had significantly longer progression-free survival (PFS) and OS than patients with a higher pretreatment MLR (p = 0.0067; p = 0.00069). The OS nomogram integrating MLR, performance status (PS) score, and body mass index (BMI) achieved a C-index of 0.770 (95%CI 0.645–0.896). The area under the ROC curve (AUC) value of the nomogram predicting 12-, 18-, and 24-month OS rates were 0.855, 0.792, and 0.744, respectively, which were higher than the clinical TNM staging system or the MLR. Stratified by the nomogram-generated scores, three risk groups (low, moderate, and high) in survival curves manifested a distinct difference (p < 0.0001). Conclusion. MLR emerged as an independent predictive factor for PFS and OS in treatment-naive unresectable ESCC patients treated with chemoimmunotherapy. The constructed nomogram of MLR and clinical parameters was a reliable model for prognostic estimation.


  • Open Access

    Acute Care of At-Risk Newborns (ACORN) Education Program Improves Neonatal Care in Chinese County Hospitals

    by K Aziz, X Ma, L Du, D McMillan, Sk Lee, J Lockyer, N Singhal

    K Aziz, X Ma, L Du, D McMillan, SK Lee, J Lockyer, N Singhal; Acute Care of At-Risk Newborns (ACORN) Education Program Improves Neonatal Care in Chinese County